Discover the Phase I trial results of a novel TAG vaccine aimed at enhancing immune responses in cancer therapy. Click here to read.

PHASE I TRIAL OF TGF-SS2 ANTISENSE-GMCSF GENE MODIFIED AUTOLOGOUS TUMOR CELL (TAG) VACCINE

Tuesday, July 26, 2011

Read the Story Here

Related Posts

Discover more posts like this.

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

Sep 5, 2024

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab- Paclitaxel in Patients with Advanced Solid Tumors

Sep 5, 2024

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

Aug 23, 2024

Dr. Minal Barve
See All Posts